Arcutis Biotherapeutics, Inc.
ARQTDrugs in Pipeline
17
Phase 3 Programs
10
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ARQT Earnings Report
EPS Est: $0.09 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
How ARQT's past catalysts played out
Roflumilast Cream
Atopic Dermatitis Eczema
Topical roflumilast
Chronic Plaque Psoriasis
Roflumilast Cream 0.15%
Atopic Dermatitis Eczema
Roflumilast Cream 0.05%
Atopic Dermatitis
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
Atopic Dermatitis Eczema
Roflumilast 0.3% cream
Chronic Plaque Psoriasis
Roflumilast Foam 0.3%
Scalp Psoriasis
ARQ-151 0.3% cream
Chronic Plaque Psoriasis
Roflumilast Foam
Seborrheic Dermatitis
ARQ-151 Active
Atopic Dermatitis Eczema
ARQ-252 cream 0.3%
Chronic Hand Eczema
ARQ-151 cream 0.3%
Psoriasis
ARQ-154
Seborrheic Dermatitis
Roflumilast
Plaque Psoriasis
ARQ-151 cream 0.5%
Psoriasis
ARQ-151 cream 0.05%
Atopic Dermatitis (Eczema)
Roflumilast Cream 0.3%
Plaque Psoriasis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Roflumilast Cream | Phase 3 | Atopic Dermatitis Eczema | - | - |
Topical roflumilast | Phase 3 | Chronic Plaque Psoriasis | - | - |
Roflumilast Cream 0.15% | Phase 3 | Atopic Dermatitis Eczema | - | - |
Roflumilast Cream 0.05% | Phase 3 | Atopic Dermatitis | - | - |
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% | Phase 3 | Atopic Dermatitis Eczema | - | - |
Roflumilast 0.3% cream | Phase 3 | Chronic Plaque Psoriasis | - | - |
Roflumilast Foam 0.3% | Phase 3 | Scalp Psoriasis | - | - |
ARQ-151 0.3% cream | Phase 3 | Chronic Plaque Psoriasis | - | - |
Roflumilast Foam | Phase 3 | Seborrheic Dermatitis | - | - |
ARQ-151 Active | Phase 3 | Atopic Dermatitis Eczema | - | - |
ARQ-252 cream 0.3% | Phase 2 | Chronic Hand Eczema | - | - |
ARQ-151 cream 0.3% | Phase 2 | Psoriasis | - | - |
ARQ-154 | Phase 2 | Seborrheic Dermatitis | - | - |
Roflumilast | Phase 2 | Plaque Psoriasis | - | - |
ARQ-151 cream 0.5% | Phase 2 | Psoriasis | - | - |
ARQ-151 cream 0.05% | Phase 2 | Atopic Dermatitis (Eczema) | - | - |
Roflumilast Cream 0.3% | Phase 2 | Plaque Psoriasis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Arcutis Biotherapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 17 drug candidates in Arcutis Biotherapeutics, Inc.'s (ARQT) pipeline across Phase 3, Phase 2. Its lead program is Roflumilast Cream (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Arcutis Biotherapeutics, Inc.'s next FDA catalyst?→
Arcutis Biotherapeutics, Inc.'s (ARQT) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ARQT biotech catalysts?→
Add ARQT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Arcutis Biotherapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.